Use of Anticholinergic and Antifungal Pharmacotherapy for the Management of Bronchorrhea in a Patient With BRAF-Mutated Adenocarcinoma of the Lung

J Pain Symptom Manage. 2020 Jan;59(1):e14-e16. doi: 10.1016/j.jpainsymman.2019.10.001. Epub 2019 Oct 11.

Authors

Fabian Leo¹, Lisa Alexander², Hannes Semper³, Christian Grohé³

Affiliations

¹ Department of Respiratory Medicine, ELK Thorax Center (Evangelische Lungenklinik Berlin), Berlin, Germany. Electronic address: fabian.leo@elk-berlin.de.
² Department of Respiratory Medicine, ELK Thorax Center (Evangelische Lungenklinik Berlin), Berlin, Germany; Charité University Medicine, Berlin, Germany.
³ Department of Respiratory Medicine, ELK Thorax Center (Evangelische Lungenklinik Berlin), Berlin, Germany.

PMID: 31610268
DOI: 10.1016/j.jpainsymman.2019.10.001

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma of Lung / complications*
Adenocarcinoma of Lung / genetics
Antifungal Agents / therapeutic use*
Bronchial Diseases / drug therapy*
Bronchial Diseases / etiology
Cholinergic Antagonists / therapeutic use*
Humans
Lung Neoplasms / complications*
Lung Neoplasms / genetics
Male
Middle Aged
Proto-Oncogene Proteins B-raf / genetics*
Treatment Outcome

Substances

Antifungal Agents
Cholinergic Antagonists
BRAF protein, human
Proto-Oncogene Proteins B-raf